Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of JW0201 and C2103 or C2104
NCT05463497Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Maximum Plasma Concentration at Steady State up to 24 hours and Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Steady State up to 24 hours. Started Jan 2022; status: completed.
02
Drugs
anagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05463497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463497.